What is new for monoamine neurotransmitter disorders?

Journal of Inherited Metabolic Disease

Volumn 37, Issue 4, 2014, Pages 619-626

  Marecos, Clara ^a   Ng, Joanne ^a,b   Kurian, Manju A ^a,b  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE TRANSPORTER; NEUROTRANSMITTER; SEPIAPTERIN REDUCTASE; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BIOGENIC AMINE; VESICULAR NEUROTRANSMITTER TRANSPORTER;

AROMATIC LEVO AMINO ACID DECARBOXYLASE DEFICIENCY; CEREBRAL PALSY; CONFERENCE PAPER; DISEASE CLASSIFICATION; DOPAMINE TRANSPORTER DEFICIENCY SYNDROME; ENZYME DEFICIENCY; HUMAN; METABOLIC DISORDER; MONOAMINE NEUROTRANSMITTER DISORDER; PHENOTYPE; SECONDARY NEUROTRANSMITTER DISEASE; SEPIAPTERIN REDUCTASE DEFICIENCY; TYROSINE 3 MONOOXYGENASE DEFICIENCY; VESICULAR MONOAMINE TRANSPORTER DISEASE; AMINO ACID METABOLISM, INBORN ERRORS; BRAIN DISEASES, METABOLIC, INBORN; DEFICIENCY; DYSTONIA; DYSTONIC DISORDERS; GENETICS; METABOLISM; METABOLISM, INBORN ERRORS; PSYCHOMOTOR DISORDERS; SYNDROME;

AMINO ACID METABOLISM, INBORN ERRORS; AROMATIC-L-AMINO-ACID DECARBOXYLASES; BIOGENIC MONOAMINES; BRAIN DISEASES, METABOLIC, INBORN; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DYSTONIA; DYSTONIC DISORDERS; HUMANS; METABOLISM, INBORN ERRORS; NEUROTRANSMITTER AGENTS; PSYCHOMOTOR DISORDERS; SYNDROME; VESICULAR NEUROTRANSMITTER TRANSPORT PROTEINS;

EID: 84904095168     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-014-9697-4     Document Type: Conference Paper

References (46)

1. Allen GF, Land JM, Heales SJ (2009) A new perspective on the treatment of aromatic L-amino acid decarboxylase deficiency. Mol Genet Metab 97(1):6-14
2. Blackstone C (2009) Infantile parkinsonism-dystonia: a dopamine "transportopathy". J Clin Invest 119:1455-1458
3. Blackstone C (2011) Infantile parkinsonism-dystonia due to dopamine transporter gene mutations: another genetic twist. Lancet Neurol 10(1):24-25
4. Bonafé L, Tho{combining double acute accent}ny B, Penzien JM, Czarnecki B, Blau N (2001a) Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopter-independent monoamine-neurotransmitter deficiency without hyperphenylalaninemia. Am J Hum Genet 69:269-277
5. Bonafé L, Thöny B, Leimbacher W, Kierat L, Blau N (2001b) Diagnosis of dopa-responsive dystonia and other tetrahydrobiopterin disorders by the study of biopterin metabolism in fibroblasts. Clin Chem 47(3):477-485 (Pubitemid 32222462)
6. Brasil S, Viecelli HM, Meili D et al (2011) Pseudoexom exclusion by antisense therapy in 6-Pyruvoyl -tetrahydrobiopterin synthase deficiency. Hum Mutat 32:1019-1027
7. Brun L, Ngu LH, Keng WT (2010) Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology 75(1):64-71
8. Cawello W, Kim SR, Braun M, Elshoff JP, Ikeda J, Funaki T (2013) Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects. Clin Drug Investig. doi:10.1007/s40261-013-0150-5
9. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L (2009) Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27(3):275-280
10. Chang Y, Sharma R, Marsh J et al (2004) Levodopa-responsive aromatic L-amino acid decarboxylase deficiency. Ann Neurol 55(3):435-438 (Pubitemid 38269598)
11. Chi CS, Lee HF, Tsai CR (2012) Tyrosine hydroxylase deficiency in Taiwanese infants. Pediatr Neurol 46(2):77-82
12. De Grandis E, Serrano M, Pérez-Dueñas B et al (2010) Cerebrospinal fluid alterations of the serotonin product, 5-hydroxyindolacetic acid, in neurological disorders. J Inherit Metab Dis 33(6):803-809
13. Eberling JL, Jaqust WJ, Christine CW et al (2008) Results from phase 1 safety trial of hAADC gene therapy for Parkinson disease. Neurology 80:1980-1983
14. Espay AJ, Chen R (2013) Myoclonus. Continuum (Minneap Minn) 19 (5 Movement Disorders):1264-86
15. Fernandez-Alvarez E (2009) Movement disorders in children: recent advances in management. Indian J Pediatr 76:531-536
16. Friedman J, Hyland K, Blau N, MacCollin M (2006) Dopa-responsive hypersomnia and mixed movement disorder due to sepiapterin reductase deficiency. Neurology 67:2032-2035 (Pubitemid 44967384)
17. Friedman J, Roze E, Abdenau JE et al (2012) Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol 71:520-530
18. Garcia-Cazorla A, Duarte S, Serrano M et al (2008) Mitochondrial diseases mimicking neurotransmitter defects. Mitochondrion 8(3):273-278
19. Giovanniello T, Leuzzi V, Carducci C et al (2007) Tyrosine hydroxylase deficiency presenting with a biphasic clinical course. Neuropediatrics 38(4):213-215
20. Henriksen FH, Yasmeen S, Skjørringe T et al. (2012) Atypical dopamine transporter deficiency syndrome in two adult males with molecular characterisation of new transporter variants. New Orleans, LA: Soc Neurosci Meet Plann 2012, Poster 042
21. Hwu WL, Muramatsu S, Tseng SH et al (2012) Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci Transl Med 4(134):134ra61
22. Hyland K, Surtess RAH, Rodeck C, Clayton PT (1992) Aromatic l-amino acid decarboxylase deficiency: clinical features, diagnosis and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 42:1980-1988
23. Kurian MA (2013) What is the role of dopamine in childhood neurological disorders? Dev Med Child Neurol 55:490-496
24. Kurian M, Gissen P, Smith M, Heales S, Clayton P (2011a) The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol 10:721-733
25. Kurian MA, Li Y, Zhen J et al (2011b) Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol 10(1):54-62
26. Kurian MA, Zhen J, Cheng SY et al (2009) Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. J Clin Invest 119(6):1595-1603
27. Lee HF, Tsai CR, Chi CS, Chang TM, Lee HJ (2009) Aromatic L-amino acid decarboxylase deficiency in Taiwan. Eur J Paediatr Neurol 13(2):135-140
28. Leuzzi V, Carducci C, Tolve M, Giannini MT, Angeloni A, Carducci C (2013) Very early pattern of movement disorders in sepiapterin reductase deficiency. Neurology 81(24):2141-2142
29. Lohmann E, Koroglu Ç, Hanagasi H, Dursun B, Tasan E, Tolun A (2012) A homozygous frameshift mutation of sepiapterin reductase gene causing parkinsonism with onset in childhood. Parkinsonism Relat Disord 18(2):191-193
30. Mastrangelo M, Caputi C, Galosi S, Giannini MT, Leuzzi V (2013) Transdermal rotigotine in the treatment of aromatic L-amino acid decarboxylase deficiency. Mov Disord 28(4):556-557
31. Molero-Luis M, Serrano M, Ormazábal A et al (2013) Homovanillic acid in cerebrospinal fluid of 1388 children with neurological disorders. Dev Med Child Neurol 55(6):559-566
32. Moran MM, Allen NM, Treacy EP, King MD (2011) "Stiff neonate" with mitochondrial DNA depletion and secondary neurotransmitter defects. Pediatr Neurol 45(6):403-405
33. Neville BG, Parascandalo R, Farrugia R, Felice A (2005) Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain 128(10):2291-2296 (Pubitemid 41407969)
34. Ng J, Tuschl K, Kinali et al (2013) TH gene-negative infantile onset severe dopamine deficiency syndrome: a novel neurotransmitter disorder? Dev Med Child Neurol 5(S1):15
35. Ng J, Zhen J, Meyer E et al. (2014) Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain. doi:10.1093/brain/awu022
36. Pons R, Ford B, Chiriboga CA et al (2004) Aromatic amino acid decarboxylase deficiency: clinical features, treatment, prognosis. Neurology 62:1058-1065 (Pubitemid 38456497)
37. Pons R, Syrengelas D, Youroukos S et al (2013) Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency. Mov Disord 28(8):1058-1063
38. Rilstone J, Alkhater R, Minassian B (2013) Brain dopamine-serotonin vesicular transport disease and its treatment. N Engl J Med 368:543-550
39. Stamelou M, Mencacci NE, Cordivari C et al (2012) Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. Neurology 79(5):435-441
40. Swoboda K, Furukawa Y (2008) Tyrosine hydroxylase deficiency. GeneReviewsTM. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK1437/ in December 2013
41. Tay SK, Poh KS, Hyland K et al (2007) Unusually mild phenotype of AADC deficiency in 2 siblings. Mol Genet Metab 91(4):374-378 (Pubitemid 47043504)
42. Tormenti MJ, Tomycz ND, Coffman KA, Kondziolka D, Crammond DJ, Tyler-Kabara EC (2011) Bilateral subthalamic nucleus deep brain stimulation for dopa-responsive dystonia in a 6-year-old child. J Neurosurg Pediatr 7(6):650-653
43. Verbeek MM, Willemsen MA, Wevers RA et al (2008) Two Greek siblings with sepiapterin reductase deficiency. Mol Genet Metab 94(4):403-409
44. Willemsen MA, Verbeek MM, Kamsteeg EJ et al (2010) Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain 133(6):1810-1822
45. Yeung WL, Wong VC, Chan KY et al (2011) Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency. J Child Neurol 26(2):179-187
46. Zorzi G, Redweik U, Trippe H, Penzien JM, Thöny B, Blau N (2002) Detection of sepiapterin in CSF of patients with sepiapterin reductase deficiency. Mol Genet Metab 75:174-177 (Pubitemid 34971611)